Martin Cash has been writing a column and business news at the Free Press since 1989. Over those years he’s written through a number of business cycles and the rise and fall (and rise) in fortunes of many local businesses.
He grew up in suburban Toronto in a family of seven where his siblings and friends from back in the day still don’t believe Martin has been a business chronicler all these years, never having shown a propensity for economics or high finance in his younger days.
He studied history and philosophy at the University of Toronto and journalism at Ryerson Polytechnical Institute (it had not yet matured into a university).
One of his first professional reporting assignments, as a weekend reporter at the Globe and Mail, was to cover a water-skiing exhibition by a blind skier who tragically crashed into a ski-jump ramp on the lake, giving Martin his first big break.
He arrived in Manitoba to take a position at the Thompson Citizen on a frosty morning in January 1985, and has been calling himself a proud Manitoban ever since.
A short stint covering the Manitoba Legislature some years ago firmed up his acquired taste for the more fact-based dynamic of the business world.
Martin was a finalist for a National Newspaper Award in 2001 for work he produced for the Free Press on a bitter strike at Versatile Tractors. He has recently become a go-to judge of business competitions for the city’s bustling entrepreneurial community.
He and his wife Susan Brasher have two beautiful daughters — Madi, an accomplished furniture designer, and Emma, a student at the U of W.
Recent articles of Martin Cash
The latest tranche of recipients of grants from the provinces’ Innovation Growth Fund — $900,000 for 12 projects — was announced this week.
The program provides up to $100,000 in non-repayable grants on a 50-50 cost-sharing basis for projects that develop and commercialize innovative products or processes.
Companies receiving grants include:
● Novel Biotechnology Inc.: $100,000, testing a new manufacturing process that builds one of the key materials needed for production and research on mRNA vaccines, including those developed for COVID-19